To examine whether demethylation-mediated reconstitution of STING and subsequent rescue of STING signaling in STINGlow melanoma cells could improve agonist-induced antitumor immune responses in vivo, we developed subcutaneous tumors of B16-F10 and Yumm1.7 in STINGgt/gt mice and treated them intratumorally with a combination of 5AZADC and ADU-S100 (Fig. 4a). This evidence concerns the gene STING1 and melanoma.